- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00752596
Compassionate Use Study of 125 mg Per Day of Azimilide Dihydrochloride in One Patient
January 31, 2017 updated by: Forest Laboratories
Compassionate Use Study to Assess the Long Term Safety of 125 mg Per Day of Oral Azimilide Dihydrochloride in One Patient Following Termination of the SHIELD Open-label Study 2001060
This is an open-label, long term compassionate use study of 125 mg per day of azimilide 2HCl in a patient who completed two other protocols (2000098 and 2001060.
Study Overview
Study Type
Interventional
Enrollment (Actual)
1
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Arizona
-
Scottsdale, Arizona, United States, 85251
- Research Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- No inclusion criteria as the patient to be included is this compassionate use protocol is currently receiving azimilide therapy
Exclusion Criteria:
- Currently taking Class I or other Class III antiarrhythmic drug or other drugs that may prolong QT interval.
- Is unwilling or unable to give or understand informed consent.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
1 tablet of 125 mg/day of azimilide 2HCl, oral
|
One tablet of 125 mg/day azimilide 2HCl, taken until the study is terminated
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
There was no outcome measure in this compassionate use
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2005
Primary Completion (Actual)
July 1, 2006
Study Completion (Actual)
July 1, 2006
Study Registration Dates
First Submitted
September 11, 2008
First Submitted That Met QC Criteria
September 12, 2008
First Posted (Estimate)
September 15, 2008
Study Record Updates
Last Update Posted (Estimate)
February 1, 2017
Last Update Submitted That Met QC Criteria
January 31, 2017
Last Verified
January 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2005076
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Congestive Heart Failure
-
Echosense Ltd.WithdrawnCongestive Heart Failure (CHF)United States
-
Corthera, Inc.(formerly BAS Medical, Inc.), a member...TerminatedCongestive Heart Failure (CHF)Russian Federation
-
Meir Medical CenterUnknown
-
Adnan Kastrati, MDBiotronik SE & Co. KGCompleted
-
Signature Medical, Inc.WithdrawnHeart Failure,Congestive
-
Nihon KohdenTerminatedHeart Failure,CongestiveUnited States
-
ELA Medical, Inc.Approved for marketing
-
Abbott Medical DevicesCompletedCongestive Heart Failure TreatedItaly
-
Echosense Ltd.Terminated
-
Magenta Medical Ltd.TerminatedCongestive Heart Failure | Heart Failure, Congestive | Acute Heart FailureCroatia, Belgium, Serbia
Clinical Trials on Azimilide 2HCl
-
Human Genome Sciences Inc.CompletedAdvanced Solid TumorsUnited States
-
Daiichi Sankyo, Inc.CompletedSolid TumorsUnited States
-
Daiichi Sankyo, Inc.CompletedAcute Myeloid LeukemiaUnited States, Spain, Netherlands, Canada, France, Germany, United Kingdom, Italy, Poland
-
Forest LaboratoriesCompletedArrhythmiaUnited States, Canada, Germany, Belgium, France, Italy, Netherlands, Poland, Spain
-
Forest LaboratoriesCompletedArrhythmiasUnited States, Canada, Poland, Germany, Spain, Belgium, France
-
Forest LaboratoriesTerminatedHeart Diseases | Cardiovascular Diseases | Arrhythmias, Cardiac | Implantable Cardioverter DefibrillatorUnited States, Belgium, Canada, Czech Republic, Denmark, France, Germany, Israel, Italy, Netherlands, Poland, Spain, Sweden
-
Forest LaboratoriesCompletedAtrial FibrillationUnited States, Canada
-
Forest LaboratoriesCompleted
-
Forest LaboratoriesCompletedEfficacy and Safety of Azimilide in the Prophylactic Treatment of Patients With Atrial Fibrillation.Atrial FibrillationUnited States, Canada
-
Forest LaboratoriesCompletedAtrial FibrillationGermany, France, Belgium, Hungary, Italy, Netherlands, Poland, Russian Federation, Spain